From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)
Main author (n) | Chang (25*, 7#) | Aquilani (110) | Anink (26) | Lovell (106) | Leong (39) | Iglesias (18) | Windschall (24) | Hissink Muller (19) | Foeldvari (22) |
---|---|---|---|---|---|---|---|---|---|
Medication type | Etanercept Adalimumab Infliximab | Etanercept | Etanercept | Etanercept Adalimumab Infliximab | Etanercept Adalimumab Infliximab | Etanercept Adalimumab Infliximab | Etanercept | Etanercept | Etanercept |
Time in inactive disease, months, mean (range) | unknown | 14.6 | at least 6 | at least 6 | al least 6 | 12.2 | at least 18 | 5.8 (3-6) | unknown |
Follow up duration, months | unknown | 12 | 6 | 8 | 8 | unknown | unknown | unknown | unknown |
% relapse after withdrawal | 78%, 76% | 60% | 46.2% | 36.8% | 46.2% | 77.8% | 50% | 26.3% | 59.1% |
Time to relapse, months, mean (range) and/or [median (range)] | unknown | [4.3] | unknown | 7, [8.3] | unknown | 3 | 8.4 (4-72) | [3 (3-6.8)] | [7] |
% relapse after 6 months | 47%, 48% | 40% | 46.2% | Â | Â | Â | Â | Â | Â |
% relapse after 8 months | Â | Â | Â | 36.8% | 46.2% | Â | Â | Â | Â |
% relapse after 12 months | 78%, 76% | 60% | Â | Â | Â | Â | Â | Â | Â |